Neurofilaments as biomarkers in neurological disorders

M Khalil, CE Teunissen, M Otto, F Piehl… - Nature Reviews …, 2018 - nature.com
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …

The potential of serum neurofilament as biomarker for multiple sclerosis

S Bittner, J Oh, EK Havrdová, M Tintoré, F Zipp - Brain, 2021 - academic.oup.com
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis

G Disanto, C Barro, P Benkert, Y Naegelin… - Annals of …, 2017 - Wiley Online Library
Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

C Barro, P Benkert, G Disanto, C Tsagkas, M Amann… - Brain, 2018 - academic.oup.com
Neuro-axonal injury is a key factor in the development of permanent disability in multiple
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

J Kuhle, H Kropshofer, DA Haering, U Kundu… - Neurology, 2019 - AAN Enterprises
Objective To assess the value of blood neurofilament light chain (NfL) as a biomarker of
recent, ongoing, and future disease activity and tissue damage and its utility to monitor …

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and …

J Kuhle, C Barro, U Andreasson, T Derfuss… - Clinical Chemistry and …, 2016 - degruyter.com
Background: Neuronal damage is the morphological substrate of persisting neurological
disability. Neurofilaments (Nf) are specific cytoskeletal proteins of neurons and their …

Neurofilaments: neurobiological foundations for biomarker applications

AR Gafson, NR Barthélemy, P Bomont, RO Carare… - Brain, 2020 - academic.oup.com
Interest in neurofilaments has risen sharply in recent years with recognition of their potential
as biomarkers of brain injury or neurodegeneration in CSF and blood. This is in the context …

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis

D Rotstein, X Montalban - Nature Reviews Neurology, 2019 - nature.com
Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

The cerebrospinal fluid in multiple sclerosis

F Deisenhammer, H Zetterberg, B Fitzner… - Frontiers in …, 2019 - frontiersin.org
Investigation of cerebrospinal fluid (CSF) in the diagnostic work-up in suspected multiple
sclerosis (MS) patients has regained attention in the latest version of the diagnostic criteria …

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

J Gaiottino, N Norgren, R Dobson, J Topping, A Nissim… - PloS one, 2013 - journals.plos.org
Objective Neuronal damage is the morphological substrate of persisting neurological
disability. Neurofilaments (Nf) are cytoskeletal proteins of neurons and their release into …